03/30/2026
https://acrobat.adobe.com/id/urn:aaid:sc:VA6C2:7b2e9643-a9c8-4958-8903-8116d59bd8cc
By our fellow: Dr. Yu Ozawa
Findings
💡Genomic prostate score (GPS, Oncotype) improves prediction of adverse pathology at radical prostatectomy when added to MRI and PSA density, particularly in intermediate-risk patients.
💡Its value is most pronounced in intermediate risk cases where decision-making between active surveillance and definitive therapy remains clinically uncertain, rather than in clinically low-risk groups (selective use)
Many thanks to all who contributed to and supported this work.